Sangamo On A Roll, Clarifies Timelines And Catalysts, Takes On CRISPR
This article was originally published in The Pink Sheet Daily
Executive Summary
Sangamo used 2013 to progress its pipeline, to raise money and to acquire a company. The momentum carried into the first quarter of 2014 with the Biogen partnership and a jump in share price that suggested that investors finally may have bought into the gene therapy company’s unique story.